On October 13, 2026, Swiss drugmaker Roche agreed to license global rights to an experimental RNAi obesity therapy from Shanghai-based Rona Therapeutics for up to $1.16 billion. Rona receives up to $100 million in upfront and near-term payments and remains eligible for $1.06 billion in milestones plus royalties. The pact marks Roche's seventh deal in China in 2026 as it builds a weight-loss portfolio alongside enicepatide to challenge market leaders Eli Lilly and Novo Nordisk.
Roche's deal with Rona Therapeutics
- ▪The experimental obesity and metabolic disease therapy licensed by Roche from Rona Therapeutics is an RNA interference (RNAi) candidate targeting activin receptor-like kinase 7 (ALK7)
- ▪The licensing agreement with Shanghai-based Rona Therapeutics marks the seventh transaction executed by Swiss drugmaker Roche with a Chinese biotech entity in 2026
- ▪Under the October 13, 2026 licensing agreement between Roche and Rona Therapeutics, Rona will receive up to $100 million in upfront and near-term payments, with eligibility for an additional $1.06 billion in milestone payments plus tiered global sales royalties
- ▪On October 13, 2026, Swiss drugmaker Roche agreed to license worldwide rights to an experimental obesity and metabolic disease therapy from Shanghai-based biotech firm Rona Therapeutics in a deal worth up to $1.16 billion
Roche's weight-loss drug portfolio
- ▪Swiss drugmaker Roche is actively expanding its development portfolio of weight-loss therapies to establish a presence in the metabolic disease market
- ▪In September 2026, Roche reported positive mid-stage clinical trial results for enicepatide, an investigational candidate for obesity and diabetes that reduced body weight and lowered blood sugar levels
Competition in the obesity market
- ▪Pharmaceutical companies including Roche are vying to develop novel weight-loss drugs to challenge Eli Lilly and Novo Nordisk's dominance in the obesity treatment sector
- ▪The global market for weight-loss and obesity pharmaceuticals is currently dominated by drugmakers Eli Lilly and Novo Nordisk
Debatable claims
- ▪Billion-dollar obesity drug licensing deals drive up patient costs
- ▪Western drugmakers' reliance on Chinese biotech licensing poses strategic health risks
- ▪Massive corporate investment in obesity drugs starves research into higher-mortality diseases
Story comments
Loading comments…